Proton pump inhibitor use and fracture risk - effect modification by histamine H1 receptor blockade. Observational case-control study using National Prescription Data.
about
Proton Pump Inhibitors and the Risk for Fracture at Specific Sites: Data Mining of the FDA Adverse Event Reporting System.A review of lifestyle, smoking and other modifiable risk factors for osteoporotic fractures.Proton Pump Inhibitors and the Risk of Osseointegrated Dental Implant Failure: A Cohort Study.A Prospective, Placebo-Controlled Pilot Evaluation of the Effect of Omeprazole on Serum Calcium, Magnesium, Cobalamin, Gastrin Concentrations, and Bone in CatsThe relationship between long-term proton pump inhibitor therapy and skeletal frailty.A Proton Pump Inhibitor in the Reformulation Setting: Bioequivalence and Potential Implications for Long-Term Safety.A Matched Comparison of Per Oral Endoscopic Myotomy to Laparoscopic Heller Myotomy in the Treatment of Achalasia.Adverse effects of proton-pump inhibitor use in older adults: a review of the evidence.Proton pump inhibitors and risk of bone fractures.Effects of the Histamine 1 Receptor Antagonist Cetirizine on the Osteoporotic Phenotype in H(+) /K(+) ATPase Beta Subunit KO Mice.Impaired skeletal health in patients with chronic atrophic gastritis.Omeprazole suppressed plasma magnesium level and duodenal magnesium absorption in male Sprague-Dawley rats.Systemic administration of omeprazole interferes with bone healing and implant osseointegration: an in vivo study on rat tibiae.Proton-Pump Inhibitors and Long-Term Risk of Community-Acquired Pneumonia in Older Adults.Proton-pump inhibitors and risk of fractures: an update meta-analysis.Proton-pump Inhibitor Use and Fracture Risk: An Updated Systematic Review and Meta-analysis
P2860
Q33912042-68619EA7-5A7C-4918-8EE9-2BA5F481642FQ34171853-B55FA759-0562-4E8F-9909-AEC2F11FB0D0Q36170237-37921C4C-8F26-4197-8815-FDB338F72DE8Q37020253-4EDB825A-F8F1-4EA0-A0EF-0F5C988EF2B0Q37388809-7DC4C9D3-B56E-4FA8-9BE7-8D1FFFDD4D50Q38724116-F0E30B55-DCA8-4523-A7C0-5D77EB5BCE90Q38924896-4B22ECA5-AB95-4407-8E08-1D0DBD47E8F2Q40071378-34759D08-D9FA-4A88-9A7B-5E7B7082AEB6Q43426137-DAFF5FB4-6CB4-4E86-8A2B-E84A1DB89C95Q50931979-564CAE17-BED7-499B-9AA1-CAA8985F8138Q50933424-92F49137-6BC2-4E8E-9D9F-8A7513FC1715Q51315381-53637A5E-7C97-4228-ABC2-CDFBE1DEBA2AQ51578494-9B2F71B7-30E3-4121-9733-AB73DD765EC0Q52574981-20D133C0-4716-419F-BE4E-E5571347D446Q55059359-289B000E-5C1D-4E6D-A636-FFE915610F24Q58780145-7DE2765D-2F1D-4C3A-92B8-92938E0CB11F
P2860
Proton pump inhibitor use and fracture risk - effect modification by histamine H1 receptor blockade. Observational case-control study using National Prescription Data.
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Proton pump inhibitor use and ...... ng National Prescription Data.
@ast
Proton pump inhibitor use and ...... ng National Prescription Data.
@en
type
label
Proton pump inhibitor use and ...... ng National Prescription Data.
@ast
Proton pump inhibitor use and ...... ng National Prescription Data.
@en
prefLabel
Proton pump inhibitor use and ...... ng National Prescription Data.
@ast
Proton pump inhibitor use and ...... ng National Prescription Data.
@en
P1433
P1476
Proton pump inhibitor use and ...... ing National Prescription Data
@en
P2093
Peter Vestergaard
P304
P356
10.1016/J.BONE.2013.08.013
P577
2013-08-22T00:00:00Z